Lite Strategy Inc
LITS
Company Profile
Business description
Lite Strategy Inc is focused on the clinical development of novel therapies for cancer. The company's portfolio of drug candidates includes voruciclib, an oral cyclin-dependent kinase 9 (CDK9) inhibitor and zandelisib, an oral, once-daily, selective PI3K inhibitor. It is a clinical-stage pharmaceutical company committed to the development of novel and differentiated cancer therapies intended to improve outcomes for patients.
Contact
9920 Pacific Heights Boulevard
Suite 150
San DiegoCA92121
USAT: +1 858 369-7100
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
30 June 2026
Employees
4
Stocks News & Analysis
stocks
Sales shine but broader macro outlook darkens for this ASX share
US stores are struggling, but our investment thesis hinges on the Australian rollout.
stocks
Chart of the Week: US equity market trading at an attractive discount
The latest from our Chief US Market Strategist.
stocks
Undervalued ASX share retains wide moat rating despite regulatory pressures
Proposed price regulation impacts our fair value.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,168.90 | 43.80 | 0.48% |
| CAC 40 | 8,245.80 | 18.07 | -0.22% |
| DAX 40 | 23,806.99 | 273.64 | -1.14% |
| Dow JONES (US) | 48,185.80 | 275.88 | 0.58% |
| FTSE 100 | 10,603.48 | 5.40 | -0.05% |
| HKSE | 25,752.40 | 140.62 | -0.54% |
| NASDAQ | 22,822.42 | 187.42 | 0.83% |
| Nikkei 225 | 56,265.77 | 370.45 | 0.66% |
| NZX 50 Index | 13,191.69 | 82.12 | -0.62% |
| S&P 500 | 6,824.66 | 41.85 | 0.62% |
| S&P/ASX 200 | 8,973.20 | 57.80 | 0.65% |
| SSE Composite Index | 3,966.17 | 28.83 | -0.72% |